Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?

被引：18
作者：
Chien, Amy Jo [1 ]
Rugo, Hope S. [1 ]
机构：
[1] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 27期
关键词：
TRASTUZUMAB; NERATINIB; LAPATINIB;
D O I：
10.1200/JCO.2017.73.5670
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3089 / +
页数：4
相关论文
共 14 条
[1]   SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors [J].
Baselga, J. ;
Cortes, J. ;
De Laurentiis, M. ;
Dieras, V. ;
Harbeck, N. ;
Hsu, J. ;
Jin, H. ;
Schimmoller, F. ;
Wilson, T. R. ;
Im, Y-H ;
Jacot, W. ;
Krop, I. E. ;
Verma, S. .
CANCER RESEARCH, 2016, 76
[2]   HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor [J].
Ben-Baruch, Noa Efrat ;
Bose, Ron ;
Kavuri, Shyam M. ;
Ma, Cynthia X. ;
Ellis, Matthew J. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (09) :1061-1064
[3]   Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial [J].
Cameron, David ;
Casey, Michelle ;
Oliva, Cristina ;
Newstat, Beth ;
Imwalle, Bradley ;
Geyer, Charles E. .
ONCOLOGIST, 2010, 15 (09) :924-934
[4]   Cell-free circulating tumour DNA as a liquid biopsy in breast cancer [J].
De Mattos-Arruda, Leticia ;
Caldas, Carlos .
MOLECULAR ONCOLOGY, 2016, 10 (03) :464-474
[5]   BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment [J].
Di Leo, A. ;
Lee, K. Seok ;
Ciruelos, E. ;
Lonning, P. ;
Janni, W. ;
O'Regan, R. ;
Reynier, M-A Mouret ;
Kalev, D. ;
Egle, D. ;
Csoszi, T. ;
Bordonaro, R. ;
Decker, T. ;
Tjan-Heijnen, V. C. ;
Blau, S. ;
Schirone, A. ;
Weber, D. ;
El-Hashimy, M. ;
Dharan, B. ;
Sellami, D. ;
Bachelot, T. .
CANCER RESEARCH, 2017, 77
[6]   Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases [J].
Freedman, Rachel A. ;
Gelman, Rebecca S. ;
Wefel, Jeffrey S. ;
Melisko, Michelle E. ;
Hess, Kenneth R. ;
Connolly, Roisin M. ;
Van Poznak, Catherine H. ;
Niravath, Polly A. ;
Puhalla, Shannon L. ;
Ibrahim, Nuhad ;
Blackwell, Kimberly L. ;
Moy, Beverly ;
Herold, Christina ;
Liu, Minetta C. ;
Lowe, Alarice ;
Agar, Nathalie Y. R. ;
Ryabin, Nicole ;
Farooq, Sarah ;
Lawler, Elizabeth ;
Rimawi, Mothaffar F. ;
Krop, Ian E. ;
Wolff, Antonio C. ;
Winer, Eric P. ;
Lin, Nancy U. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :945-+
[7]   Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial [J].
Harbeck, Nadia ;
Huang, Chiun-Sheng ;
Hurvitz, Sara ;
Yeh, Dah-Cherng ;
Shao, Zhimin ;
Im, Seock-Ah ;
Jung, Kyung Hae ;
Shen, Kunwei ;
Ro, Jungsil ;
Jassem, Jacek ;
Zhang, Qingyuan ;
Im, Young-Hyuck ;
Wojtukiewicz, Marek ;
Sun, Qiang ;
Chen, Shin-Cheh ;
Goeldner, Rainer-Georg ;
Uttenreuther-Fischer, Martina ;
Xu, Binghe ;
Piccart-Gebhart, Martine .
LANCET ONCOLOGY, 2016, 17 (03) :357-366
[8]   HER2-positive breast cancer [J].
Loibl, Sibylle ;
Gianni, Luca .
LANCET, 2017, 389 (10087) :2415-2429
[9]  
Ma C, 2017, P ANN M AM ASS CANC
[10]   Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer [J].
Ma, Fei ;
Li, Qiao ;
Chen, Shanshan ;
Zhu, Wenjie ;
Fan, Ying ;
Wang, Jiayu ;
Luo, Yang ;
Xing, Puyuan ;
Lan, Bo ;
Li, Meiying ;
Yi, Zongbi ;
Cai, Ruigang ;
Yuan, Peng ;
Zhang, Pin ;
Li, Qing ;
Xu, Binghe .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) :3105-+
12